Shizuya Yamashita
Overview
Explore the profile of Shizuya Yamashita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
259
Citations
6897
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamashita S, Fujita H, Yokota D, Morikawa-Isogai Y, Kitamoto R
J Atheroscler Thromb
. 2025 Mar;
PMID: 40024737
Aim: We evaluated the efficacy and safety of bempedoic acid, an ATP-citrate lyase inhibitor, at doses of 60, 120, and 180 mg, administered for 12 weeks in conjunction with ongoing...
2.
Matsunaga K, Harada-Shiba M, Yamashita S, Tada H, Uda A, Mori K, et al.
J Atheroscler Thromb
. 2025 Feb;
PMID: 39956559
Aim: Screening for familial hypercholesterolemia (FH) is important for reducing the incidence of cardiovascular diseases (CVDs). Cost-effectiveness was evaluated using the Kagawa FH screening model, which is a combination of...
3.
Arai H, Yamashita S, Araki E, Yokote K, Tanigawa R, Saito A, et al.
J Atheroscler Thromb
. 2025 Feb;
PMID: 39924184
Aims: Long-term safety and efficacy of pemafibrate once-daily extended-release (XR) tablets, taken in morning or evening, were evaluated in dyslipidemic patients with high triglycerides (TG). Methods: In this multicenter, randomized,...
4.
Elshorbagy A, Vallejo-Vaz A, Barkas F, Lyons A, Stevens C, Dharmayat K, et al.
Eur Heart J
. 2025 Jan;
PMID: 39801189
Background And Aims: Overweight and obesity are modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population, but their prevalence in individuals with heterozygous familial hypercholesterolaemia (HeFH) and...
5.
Tanigawa R, Nakajima A, Eguchi Y, Takahashi H, Loomba R, Suganami H, et al.
J Atheroscler Thromb
. 2024 Dec;
PMID: 39694503
Aim: In the PEMA-FL study in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), pemafibrate was shown to significantly decrease low-density lipoprotein cholesterol (LDL-C) levels. We aimed to investigate the...
6.
Janic M, Yamashita S, Su T, Rizzo M
Metabolites
. 2024 Nov;
14(11).
PMID: 39590832
Atherosclerotic cardiovascular disease is a major burden of morbidity and, despite recent therapeutic advances, is the leading cause of mortality worldwide [...].
7.
Fujii E, Ako J, Takahashi Y, Toda M, Iekushi K, Yamashita S
J Atheroscler Thromb
. 2024 Oct;
PMID: 39370270
Aims: To investigate the distribution of lipoprotein(a) (Lp(a)) and its association with atherosclerotic cardiovascular disease (ASCVD) in Japanese patients at high risk for ASCVD using a health insurance database. Methods:...
8.
Yamashita S, Araki E, Arai H, Yokote K, Tanigawa R, Saito A, et al.
J Atheroscler Thromb
. 2024 Sep;
32(3):367-384.
PMID: 39322570
Aims: Efficacy, safety, and pharmacokinetics of the selective PPARα modulator pemafibrate as once-daily extended-release (XR) tablets were compared with those of twice-daily immediate-release (IR) tablets in patients with hypertriglyceridemia. Methods:...
9.
Ishibashi S, Arai H, Yokote K, Araki E, Watanabe M, Nakanishi M, et al.
J Atheroscler Thromb
. 2024 Sep;
32(2):210-225.
PMID: 39231654
Aims: Per the package insert, pemafibrate was contraindicated for use in patients with severe renal impairment despite its biliary excretion. To validate this, we evaluated the pharmacokinetics and safety of...
10.
Proteomic Analysis of Human Chylomicron Remnants Isolated by Apolipoprotein B-48 Immunoprecipitation
Masuda D, Okada T, Sairyou M, Takafuji K, Ohama T, Koseki M, et al.
J Atheroscler Thromb
. 2024 Jul;
32(2):226-238.
PMID: 39085140
Aim: Postprandial hypertriglyceridemia (PHTG) is an independent risk factor for coronary heart diseases. PHTG exhibits accumulation of apoB-48 containing chylomicron remnants (CM-Rs) and apoB-100 containing VLDL remnants (VLDL-Rs), which are...